We are live on ! Find out more
THRD

Third Harmonic Bio
THRD

Delisted

THRD was delisted on the 30th of July, 2025.

Back to rankings

40 hedge funds and large institutions have $563M invested in Third Harmonic Bio in 2022 Q3 according to their latest regulatory filings, with 40 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

91.67% more ownership

Funds ownership: 0% → 91.67% (+92%)

Holders
40
Holders Change
+40
Holders Change %
–
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
40
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
+$197M
2
O
OrbiMed
New York
+$104M
3
BI
BVF Inc
California
+$63.1M
4
RCM
RA Capital Management
Massachusetts
+$62.6M
5
GA
General Atlantic
New York
+$53.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$207M +$197M +10,907,859 New
BI
2
BVF Inc
California
$66.4M +$63.1M +3,501,814 New
RCM
3
RA Capital Management
Massachusetts
$65.9M +$62.6M +3,475,687 New
GA
4
General Atlantic
New York
$56.1M +$53.3M +2,958,762 New
BCLSI
5
Bain Capital Life Sciences Investors
Massachusetts
$43.3M +$41.1M +2,280,082 New
DTC
6
Deep Track Capital
Connecticut
$24.1M +$22.9M +1,268,220 New
Wellington Management Group
7
Wellington Management Group
Massachusetts
$22.2M +$21.1M +1,168,554 New
CC
8
Commodore Capital
New York
$19.3M +$18.4M +1,018,569 New
RI
9
RTW Investments
New York
$11.6M +$11M +609,687 New
BC
10
Boxer Capital
California
$10.8M +$10.3M +570,417 New
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$8.93M +$8.48M +470,626 New
WP
12
Woodline Partners
California
$3.79M +$3.61M +200,063 New
AG
13
Artal Group
Luxembourg
$3.79M +$3.6M +200,000 New
SCM
14
Suvretta Capital Management
New York
$3.79M +$3.6M +200,000 New
Millennium Management
15
Millennium Management
New York
$3.38M +$3.21M +178,301 New
Vanguard Group
16
Vanguard Group
Pennsylvania
$1.9M +$1.8M +100,000 New
Alyeska Investment Group
17
Alyeska Investment Group
Illinois
$1.42M +$1.35M +75,000 New
Marshall Wace
18
Marshall Wace
United Kingdom
$1.11M +$1.05M +58,465 New
Citadel Advisors
19
Citadel Advisors
Florida
$1.09M +$1.04M +57,687 New
Goldman Sachs
20
Goldman Sachs
New York
$1.03M +$982K +54,500 New
GCM
21
Ghisallo Capital Management
Massachusetts
$759K +$721K +40,000 New
MIM
22
Monashee Investment Management
Massachusetts
$759K +$721K +40,000 New
Barclays
23
Barclays
United Kingdom
$546K +$518K +28,750 New
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$527K +$501K +27,800 New
Squarepoint
25
Squarepoint
New York
$482K +$457K +25,384 New
1
2

THRD Hedge Fund Activity: Q3 2022 in Review

40 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q3 2022, worth a combined $563M.

Buyers outnumbered sellers: 40 funds opened new THRD positions and 0 closed out — a net gain of 40 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Atlas Venture Life Science Advisors, opening a new position worth an estimated $197M.

  • 40 institutional investors held Third Harmonic Bio (THRD) as of Q3 2022, up from 0 in Q2 2022.
  • Funds reported $563M of Third Harmonic Bio stock for Q3 2022.
  • 40 funds opened new Third Harmonic Bio positions in Q3 2022 and 0 closed out, a net change of +40 holders.
  • The largest Third Harmonic Bio buyer in Q3 2022 was Atlas Venture Life Science Advisors, an estimated $197M added.

Based on aggregated 13F filings for Q3 2022.